USPTO serial 86970800
ABACCEL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 12, 2017
- Examiner
- O'ROURKE, JONATHAN RYAN
- Law office
- FILE DESTROYED
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ABACCEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karen L. Elbing
Karen L. Elbing CLARK & ELBING LLP101 FEDERAL STREET, 15TH FLOORBOSTON, MA 02110United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Scientific and technological services and research projects for the preparation of peptide and antibody libraries, and for the identification and characterisation of binding molecules, namely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects for the preparation, identification and characterisation of peptides or antibodies, namely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects for the preparation, identification and characterisation of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, or antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to antibody development strategies, namely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely scientific research and analysis in the field of antibody research and drug design; scientific and technological services and research projects in relation to multi-factor antibody optimization, namely scientific research and analysis in the field of antibody research and drug design; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and nonhuman lead antibody technology, namely scientific research and analysis in the field of antibody research and antibody optimization | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 12, 2026 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Sep 13, 2024 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Sep 13, 2024 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Sep 13, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 6, 2024 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Sep 12, 2022 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 12, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 27, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 27, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 7, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 4, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 13, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 12, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 12, 2017 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 24, 2017 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 24, 2017 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 24, 2017 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 23, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 23, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 16, 2017 | ALIE | ASSIGNED TO LIE | — |
| Feb 1, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 3, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 3, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 3, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 29, 2016 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jul 29, 2016 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 26, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 15, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 14, 2016 | NWAP | NEW APPLICATION ENTERED | — |